FDA Guidance on AI Poised to Accelerate Drug Development at Fort Detrick

A new draft guidance from the U.S. Food and Drug Administration is expected to help military medical researchers deploy artificial intelligence more effectively across the drug development lifecycle. At Fort Detrick’s Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC), staff are already integrating these updates into their processes to support the faster, safer delivery of critical medical products for service members in hazardous environments.

AI’s role in medical research is evolving rapidly. While it has already proven effective in accelerating the identification of promising drug candidates, its use is expanding into areas such as patient diagnostics and treatment planning. The new FDA guidance, titled “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products,” offers a structured seven-step method for evaluating how AI influences decisions on drug safety, efficacy, and quality. This risk-based approach adjusts documentation requirements depending on the influence the AI has over critical outcomes.

At DHA R&D-MRDC, the Office of Regulated Activities (ORA) is charged with ensuring regulatory compliance at every stage of product development. By identifying potential risks early, ORA helps researchers navigate the FDA review process more efficiently. Staff such as regulatory analyst Dr. Barima Frempong and regulatory affairs scientist Valeria Sena-Weltin are training internal teams to align their projects with these updated guidelines, emphasizing transparency in how AI models are trained and validated.

Among the AI-enabled tools already developed by DHA R&D-MRDC are the SeptiBurnAlert, which detects the risk of sepsis in burn patients, and the Hemorrhage Risk Index, which predicts bleeding risk in trauma cases. Both rely on vital-sign data and AI algorithms to support real-time clinical decisions. To maintain the accuracy and reliability of such systems, researchers must regularly assess the underlying data sets, document algorithmic changes, and guard against biases that could undermine results.

The guidance and best practices were shared in a recent “lunch and learn” event at MRDC, part of an ongoing series hosted by ORA to ensure staff stay informed of current regulatory expectations. These updates aim to keep military medical research both innovative and compliant as AI becomes increasingly integral to health care and defense readiness.

Article by multiple RFHC contributors, based upon information from a press release issued by the Medical Research and Development Command

Video Spotlight